Search research articles
Contact Us
Filters
Showing results (151-160 of 304) with videos related to
Page
of 31
Sort By:
JAMA Cardiology
|
April 7, 2024
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
Daniel Gaudet, Denes Pall, Gerald F Watts, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 2, 2015
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays, Daniel Gaudet, Robert Weiss, et al.
The American Journal of Cardiology
|
November 6, 2019
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
Daniel Gaudet, Ronen Durst, Norman Lepor, et al.
European Journal of Preventive Cardiology
|
February 24, 2021
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
Daniel Gaudet, José Luis López-Sendón, Maurizio Averna, et al.
Molecular Genetics and Metabolism
|
January 27, 2004
The c.419-420insA in the MTP gene is associated with abetalipoproteinemia among French-Canadians
Marie-Thérèse Berthier, Patrick Couture, Alain Houde, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 15, 2025
Course of Pregnancies and Occurrence of Acute Pancreatitis in Women with Chylomicronemia
Miriam Larouche, Jean Bergeron, Diane Brisson, et al.
Journal of the American College of Cardiology
|
July 9, 2021
Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
Zahid Ahmad, Robert Pordy, Daniel J Rader, et al.
International Journal of Epidemiology
|
March 29, 2016
Cohort Profile: The Saguenay Youth Study (SYS)
Zdenka Pausova, Tomas Paus, Michal Abrahamowicz, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
International Journal of Cardiology
|
November 26, 2016
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment
Robert Dufour, Jean Bergeron, Daniel Gaudet, et al.
Page
of 31
Search research articles
Search
Showing results (151-160 of 304) with videos related to
Sort By:
Page
of 31
JAMA Cardiology
|
April 7, 2024
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
Daniel Gaudet, Denes Pall, Gerald F Watts, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 2, 2015
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays, Daniel Gaudet, Robert Weiss, et al.
The American Journal of Cardiology
|
November 6, 2019
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
Daniel Gaudet, Ronen Durst, Norman Lepor, et al.
European Journal of Preventive Cardiology
|
February 24, 2021
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
Daniel Gaudet, José Luis López-Sendón, Maurizio Averna, et al.
Molecular Genetics and Metabolism
|
January 27, 2004
The c.419-420insA in the MTP gene is associated with abetalipoproteinemia among French-Canadians
Marie-Thérèse Berthier, Patrick Couture, Alain Houde, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 15, 2025
Course of Pregnancies and Occurrence of Acute Pancreatitis in Women with Chylomicronemia
Miriam Larouche, Jean Bergeron, Diane Brisson, et al.
Journal of the American College of Cardiology
|
July 9, 2021
Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
Zahid Ahmad, Robert Pordy, Daniel J Rader, et al.
International Journal of Epidemiology
|
March 29, 2016
Cohort Profile: The Saguenay Youth Study (SYS)
Zdenka Pausova, Tomas Paus, Michal Abrahamowicz, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
International Journal of Cardiology
|
November 26, 2016
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment
Robert Dufour, Jean Bergeron, Daniel Gaudet, et al.
Page
of 31